Flow cytometry is a laser-based method used to examine multiple physical and chemical parameters of single cells suspended in a fluid. By measuring how these particles scatter light and emit fluorescence, it enables the identification, quantification, and isolation of distinct cell populations.
Over the years, flow cytometry with antibody staining has been a key technique in immunology and cell biology fields, but its role in G-protein coupled receptor (GPCR) analysis is expanding rapidly thanks to the development of fluorescent ligands. Unlike traditional antibody staining, which often requires cell fixation and permeabilization, fluorescent ligands bind directly to the functional sites of receptors in live cells. This opens new avenues for studying receptor dynamics, ligand binding, and signaling in real time, offering researchers a more functional and flexible tool.

Figure 1. Schematic representation of the flow cytometry technique. Adapted from Drescher H, Weiskirchen S, Weiskirchen R. Flow Cytometry: A Blessing and a Curse. Biomedicines. 2021 Nov 4;9(11):1613.
While the use of antibodies in flow cytometry assays is well-established, particularly for surface protein detection, it comes with notable limitations in GPCR analysis:
Required by most antibody-based protocols, this step can disrupt receptor conformation and interfere with downstream signaling.
Antibodies may show inconsistent results due to differences in production lots.
Many antibodies bind to shared epitopes across proteins, leading to non-specific staining. Moreover, antibodies tend to bind to dead cells.
The activity of antibodies might influence cell biology and the read-out of results.
These limitations can impact data quality, assay reproducibility, and experimental flexibility. In this context, fluorescent ligands offer a powerful alternative to traditional antibody staining thanks to various key advantages:
They are designed to bind directly to the active site of a receptor, providing a readout of its functionality (e.g., kinetics or binding affinity) rather than just monitoring its presence.
They do not require fixation or permeabilization. This makes them ideal for live-cell flow cytometry, enabling real-time monitoring while preserving cellular physiology.
Well-characterized ligands exhibit consistent and selective binding to their target receptor, minimizing background and maximizing signal reliability.
GPCRs are particularly challenging to analyze using conventional flow cytometry antibodies due to their membrane localization, low expression, and complex conformations. Fluorescent ligands are transforming this landscape by providing new capabilities:
Unlike static measurements typical of antibodies, fluorescent ligands allow continuous observation of GPCRs interactions, providing insights into their dynamic signaling processes, including internalization and recycling upon activation.
The development of bright and stable fluorescent ligands supports high-throughput screening applications, allowing for the rapid assessment of multiple GPCR interactions and signaling pathways.
The use of high-affinity fluorescent ligands enables the detection of biased signaling pathways, which can be crucial for understanding the functional diversity of GPCRs and their therapeutic potential.
These capabilities lead to key applications in flow cytometry, such as the quantification of functional receptor expression, internalization, or ligand-receptor interactions analysis, that are often missed with antibodies.
Moreover, innovations in fluorophore chemistry, self-labeling tags, and the use of autofluorescent proteins (AFPs) have enhanced signal-to-noise ratios and photostability, reducing background interferences from autofluorescence.
Selecting the right fluorophore is essential to maximize the sensitivity and accuracy of any flow cytometry assay, particularly when studying low-abundance receptors like GPCRs. The optimization process must consider multiple factors:
Equally important is the optimization of fluorescence channels. Assigning each fluorophore to the most appropriate detector is essential to ensure clear signal separation from background. It requires a thoughtful panel design (i.e., selecting compatible fluorophores that avoid spectral overlap and match the cytometer’s laser setup) and strategic gating, which refers to identifying and isolating specific cell populations during data analysis.
Innovations such as spectral flow cytometry and fluorescence lifetime imaging have further expanded these capabilities. Accurate data analysis also relies on robust flow cytometry gating strategies that account for signal variability and sample heterogeneity, reinforcing the importance of deliberate assay design..
Fluorescent ligands represent a significant advancement for flow cytometry applications in GPCR research. They enable real-time, high-resolution, and functionally relevant assays that overcome many of the limitations of antibody-based methods. Their compatibility with live-cell analysis, higher reproducibility, and adaptability for high-throughput screening make them invaluable tools for researchers.
At Celtarys, we support this transition by offering optimized fluorescent ligands specifically designed for GPCR targets, including CELT-240 for hD2/D3 dopamine receptors and CELT-483 for the hσ1/σ2 sigma receptor. In addition, we provide detailed protocols and expert guidance to help you achieve reliable, actionable flow cytometry results.

Figure 2. CELT-240 in flow cytometry binding assays is suitable to measure the affinity of compounds for the D2/D3 receptors. Flow Cytometry validation performed in the Oncological Pharmacology Laboratory of the University of Turin.
References
Drescher H, Weiskirchen S, Weiskirchen R. Flow Cytometry: A Blessing and a Curse. Biomedicines. 2021 Nov 4;9(11):1613. doi: 10.3390/biomedicines9111613
University of Virginia Flow Cytometry Facility. Critical Aspects of Staining Cells [Internet]. Charlottesville (VA): University of Virginia; [cited 2025 May 16]. Available from: https://med.virginia.edu/flow-cytometry-facility/wp-content/uploads/sites/170/2015/10/Critical-Aspects-of-Staining-Cells.pdf
Böhme I, Beck-Sickinger AG. Illuminating the life of GPCRs. Cell Commun Signal. 2009 Jul 14;7:16. doi: 10.1186/1478-811X-7-16 Siddiqui S, Livák F. Principles of Advanced Flow Cytometry: A Practical Guide. Methods Mol Biol. 2023;2580:89-114. doi: 10.1007/978-1-0716-2740-2_5




PERTE SALUD Proyecto Nº: IDI-2025-0751
Título: TERAPIAS AVANZADAS EN INMUNOONCOLOGÍA: UNA ESTRATEGIA INNOVADORA
BASADA EN LA DEGRADACIÓN DIRIGIDA DE GPCR EN EL EJE ADENOSINÉRGICOS

EIC Pathfinder; Project name: Unisens; Universal GPCR Activity Sensor for Next Generation Drug Discovery



Esta entidad fue beneficiaria de las ayudas para la ejecución de acciones de promoción exterior de las empresas gallegas. El objetivo principal de estas ayudas es incentivar la realización de acciones de promoción exterior generadoras de ventajas competitivas. El resultado que se pretende conseguir es el impulso de las pymes y sus productos y servicios, aumentando el número de empresas de base exportadora.

Celtarys Research is beneficiary of a WomenTechEU grant supporting deep-tech start-ups led by women





Principia 2021 Program
Celtarys staff has been funded by the Xunta de Galicia within the framework of the PRINCIPIA 2021 Program of the Galician Innovation Agency (GAIN)
InnovaPEME Program
Celtarys Innovation Plan has been funded by the InnovaPEME 2022 program of the Galician Innovation Agency (GAIN)



Bonos de Innovación de Celtarys Research (026)
Para promover o desenvolvemento tecnolóxico, a innovación e unha investigación de calidade. Esta operación está financiada pola Xunta de Galicia, a través de axudas concedidas pola Axencia Galega de Innovación, dentro do programa de axudas a empresa Bonos de innovación 2022.




Celtarys Research is part of the public-private consortium developing the project PREDICTEAM
New prognostic quantitative biomarker assays for predicting patient response to immune checkpoint inhibitor (ICI) treatment





NEOTEC · CDTI — Ministerio de Ciencia e Innovación




The Project ‘New chemical conjugation technology for therapeutic targets’ has been founded by CDTI under its program NEOTEC. The NEOTEC program objective is supporting the establishment and consolidation of technology-based enterprises. A technology-based company (EBT) is a company whose activity focuses on the exploitation of products or services that require the use of technologies and knowledge developed since the research activity. The EBT base their business strategy or activity in the intensive domain of scientific and technical knowledge. Budget awarded: 416.177€ | Execution dates: 1/1/2023 – 31/03/2024
Avenida de Barcelona, 7
15706, Santiago de Compostela
A Coruña (Spain)